Today, ACI signed a coalition letter calling on the U.S. Congress to encourage the use of lower-priced biosimilar medicines, which would save lives and reduce healthcare costs. The letter was sent to the U.S. House of Representatives and U.S. Senate leadership, and it is available here online.
Today, a group of 68 nonprofits and associations sent a letter to the President cautioning him against any executive actions that may restrict access to or destabilize the supply chain for pharmaceuticals or medical devices. At this time, while supply chains for a broad range of U.S. industries are stressed due to the global COVID-19 […]
Today, ACI, along with 75 organizations and activists, sent a letter to Congress opposing Medicare-for-All legislation that includes provisions for the government to set prescription prices. The letter is available online.
Today, ACI joined 70 other organizations in opposition to the prescription drug pricing bill offered by House Speaker Nancy Pelosi. The bill would impose excise taxes up to 95% on hundreds of prescription medicines. You can read the coalition letter online. 10-15-19 Coalition Letter Opposed to Pelosi Drug Tax Plan
It’s tempting to think that legalizing drug importation would immediately give U.S. consumers access to medicines at the prices available in other developed countries. In reality, however, the Safe Importation Action Plan would expose American consumers to significant health risks while achieving meager cost reductions, if any at all. Visit Real Clear Health to lean […]
In partnership with the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS) has recently proposed that certain pharmaceuticals should be cleared for import from Canada. Although the proposal seeks to lower prices for consumers, it poses critical unintended risks to both American businesses and patients. To read why, visit Townhall.
In an effort to reverse the continuing rise of prescription drug prices, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) are mulling the idea of allowing drug imports from Canada. Their so-called “Safe Importation Action Plan,” however, is a misnomer—the policy could expose countless Americans to potentially deadly […]
Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]
Today, ACI released a coalition letter to Congress in opposition to creating an inflationary rebate penalty in Medicare Part D. You can download and print the letter here.
Americans are right to be concerned about the high out-of-pocket costs of pharmaceuticals. But targeting America’s free enterprise system is the wrong solution. Putting bureaucrats abroad in charge of deciding how our drug market operates may save some money now, but it’ll hurt consumers in the long-run. This op-ed, published in Real Clear Health, explains […]